Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Juvenile rheumatoid arthritis

Executive Summary

Draft guidelines for the clinical evaluation of anti- inflammatory and antirheumatic drugs for children were made available at the June 1 joint meeting of FDA's Arthritis and OTC Drug advisory committees. The guidelines were originally issued in 1977 and underwent minor revisions last year. The current draft updates the guidelines further with minor changes. The availability of the guidelines will be announced in a future Federal Register notice, and the Arthritis Advisory Committee will discuss them at a later meeting.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022819

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel